Related references
Note: Only part of the references are listed.First Candida auris Outbreak during a COVID-19 Pandemic in a Tertiary-Care Center in Lebanon
Fatima Allaw et al.
PATHOGENS (2021)
Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum
Renato Kovacs et al.
MICROORGANISMS (2021)
Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris
Muriel Billamboz et al.
MICROORGANISMS (2021)
Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi
Lucie Peyclit et al.
PHARMACEUTICALS (2021)
Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance
Hans Carolus et al.
JOURNAL OF FUNGI (2020)
Multidrug-Resistant Candida auris Infections in Critically III Coronavirus Disease Patients, India, April-July 2020
Anuradha Chowdhary et al.
EMERGING INFECTIOUS DISEASES (2020)
Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model
Lajos Forgacs et al.
EMERGING MICROBES & INFECTIONS (2020)
Molecular Epidemiology of Candida auris in Colombia Reveals a Highly Related, Countrywide Colonization With Regional Patterns in Amphotericin B Resistance
Patricia Escandon et al.
CLINICAL INFECTIOUS DISEASES (2019)
Candida auris Isolates of the Southern Asian and South African Lineages Exhibit Different Phenotypic and Antifungal Susceptibility Profiles In Vitro
Adrien Szekely et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2019)
Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris
Catiana Dudiuk et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Candida auris: The Canary in the Mine of Antifungal Drug Resistance
Marhiah C. Montoya et al.
ACS INFECTIOUS DISEASES (2019)
Potential Fifth Clade of Candida auris, Iran, 2018
Nancy A. Chow et al.
EMERGING INFECTIOUS DISEASES (2019)
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Christopher L. Hager et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance
Anuradha Chowdhary et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model
Christopher L. Hager et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen
John Osei Sekyere
MICROBIOLOGYOPEN (2018)
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Shawn R. Lockhart et al.
CLINICAL INFECTIOUS DISEASES (2017)
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Romuald Bellmann et al.
INFECTION (2017)
Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2016)
Killing Rates of Caspofungin in 50 Percent Serum Correlate with Caspofungin Efficacy Against Candida albicans in a Neutropenic Murine Model
Marianna Doman et al.
CURRENT DRUG DELIVERY (2016)
Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species
Andrew M. Borman et al.
MSPHERE (2016)
Candida auris sp nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital
Kazuo Satoh et al.
MICROBIOLOGY AND IMMUNOLOGY (2009)
Correlation of posaconazole minimum fungicidal concentration and time-kill test against nine Canadian species
G. Soczo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
The solubility ceiling: A rationale for continuous infusion amphotericin B therapy?
RE Lewis et al.
CLINICAL INFECTIOUS DISEASES (2003)
Share Paper
